According to a new report, published by KBV research, The Global Opioid Use Disorder (OUD) Market size is expected to reach $6.4 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.
The Methadone segment has shown a growth rate of 10.5% during (2023 - 2030). Methadone alters how the nervous system and brain react to pain so that experiences relief. The Food and Drug Administration (FDA) has given the drug approval to control pain as well as to treat OUD. Methadone assists people in achieving & maintaining recovery and reclaiming active and fulfilling lives. A comprehensive treatment program that combines counselling and other behavioral health therapies to provide patients with a whole-person approach also incorporates methadone as one of its components.
The Hospital Pharmacies segment is leading the Global Opioid Use Disorder (OUD) Market by Distribution Channel in, achieving a market value of $2.9 billion by 2030. Hospitals serve as primary medical facilities and have a large population of qualified, skilled workers who help patients receive successful treatment. Additionally, use of prescribed therapy in clinics & hospitals aids in distributing medications under medical supervision. One of the main drivers of opioid sales through hospital pharmacies is this factor. For patients with opioid use disorders to access other medications more easily, hospital pharmacies make drugs like the opioid analgesic "naloxone" readily accessible. This segment's expansion is anticipated to be fueled by all these factors.
The Oral segment is showcasing of 11.7% during (2023 - 2030). The market witnessed growth in this segment as a result of the wide availably of a number of OUD drugs in different dosage in oral form. Further, oral administration might be less complicated and uncomfortable than alternative administration methods like injection due to which they are being more preferred by patients.
The North America market dominated the Global Opioid Use Disorder (OUD) Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $2.7 billion by 2030. The Europe market is poised to grow at a CAGR of 9.4% during (2023 - 2030). Additionally, The Asia Pacific market would showcase a CAGR of 10.9% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/opioid-use-disorder-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC, and Viatris, Inc.
By Drug Class
By Route of Administration
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
